Solara Active Pharma Sciences Bundle
Who Really Controls Solara Active Pharma Sciences?
Understanding the ownership structure of a company is crucial for investors and stakeholders alike. Solara Active Pharma Sciences, a significant player in the active pharmaceutical ingredients (API) market, has a fascinating ownership journey. Unraveling Solara Active Pharma Sciences SWOT Analysis can provide valuable insights into its strategic direction and future prospects.
From its 2017 inception as an API manufacturer through a strategic demerger, Solara's ownership has evolved significantly. This article explores the key players behind Solara Active Pharma Sciences, examining its major shareholders and the influence of its board. We'll dissect the company's history, analyze its current ownership dynamics, and explore how these factors impact its operational strategies and financial performance, providing a comprehensive view of who owns Solara and the implications.
Who Founded Solara Active Pharma Sciences?
Understanding the ownership structure of Solara Active Pharma Sciences requires looking back at its origins. Unlike typical startups, Solara emerged from a demerger, which significantly shaped its initial ownership. This unique formation process is key to identifying who owns Solara.
Solara Active Pharma Sciences was created by separating the active pharmaceutical ingredients (API) businesses of two entities: Strides Shasun and Sequent Scientific Limited. This separation meant the initial ownership was distributed among the shareholders of these parent companies. Therefore, the question of who owns Solara is intrinsically tied to the shareholders of Strides and Sequent at the time of the demerger.
The demerger process determined the initial Solara shareholding. Shareholders of Strides received shares in Solara based on their existing holdings in Strides, and similarly, shareholders of Sequent received Solara shares. This method ensured that the ownership of the new company was directly proportional to the existing stakes in the parent companies.
Demerger Origins
Solara's creation involved the demerger of API businesses from Strides Shasun and Sequent Scientific Limited.
Share Distribution
Shareholders of Strides and Sequent received Solara shares based on their existing holdings.
Key Figures
Arun Kumar, founder of Strides, played a crucial role in Solara's formation.
Early Backing
Private equity investor TPG provided early backing before the demerger.
Ownership Details
Understanding the initial ownership is vital for anyone researching Solara ownership.
Share Exchange Ratio
Shareholders of Strides received 1 Solara share for every 6 Strides shares, and Sequent shareholders received 1 Solara share for every 25 Sequent shares.
Key Takeaways on Solara Ownership
The initial ownership of Solara Active Pharma Sciences was determined by the shareholders of Strides Shasun and Sequent Scientific Limited. The demerger process, completed on April 9, 2018, allocated Solara shares based on the existing holdings in the parent companies. Specifically, shareholders of Strides received 1 equity share of Solara for every 6 shares held, while Sequent shareholders received 1 Solara share for every 25 shares held. Arun Kumar, who founded Strides Pharma Science Limited in 1990 and was involved in the co-founding and development of SeQuent Scientific Limited, holds a significant position as a Founder & Non-Executive Director. Early backing for the combined entity included private equity investor TPG. For more detailed information, you can refer to this article about Solara Active Pharma Sciences.
- The demerger from Strides and Sequent formed Solara.
- Share distribution was proportional to existing holdings in the parent companies.
- Arun Kumar, a key figure, continues to be involved.
- TPG provided early financial backing.
Solara Active Pharma Sciences SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Solara Active Pharma Sciences’s Ownership Changed Over Time?
The ownership structure of Solara Active Pharma Sciences has evolved since its inception through a demerger in 2017. As of March 2025, the promoter group held 37.94% of the company's shares, reflecting an increase from 37.23% in December 2024. This shift highlights the ongoing dynamics within the company's ownership, influenced by various factors including strategic decisions and market conditions. Understanding the ownership details of companies like Solara Active Pharma Sciences is crucial for investors and stakeholders to assess the company's stability and future prospects.
Institutional investors also play a significant role in Solara's ownership structure. Foreign Institutional Investors (FIIs) held 14.63% of the shares as of March 2025, a slight decrease from 14.67% in December 2024. Mutual Funds maintained a consistent 1.28% shareholding across three schemes as of March 2025. Non-institutional investors, including individual shareholders, collectively held a substantial 44.81% of the company's shares as of March 2025. This distribution reveals the diverse investor base supporting Solara Active Pharma Sciences.
| Shareholder Category | March 2025 (%) | December 2024 (%) |
|---|---|---|
| Promoters | 37.94 | 37.23 |
| FIIs | 14.63 | 14.67 |
| Mutual Funds | 1.28 | - |
| Non-Institutional Investors | 44.81 | - |
A notable event impacting ownership was the rights issue in May-June 2024, which aimed to raise ₹449.95 crores. The company received a partial amount of ₹157.48 crores by December 31, 2024, with the remaining ₹292.47 crores to be called as needed. This financial maneuver contributed to an improved financial profile, with gearing around 1 time as of December 31, 2024. For more insights into the company's operations, you can explore the Revenue Streams & Business Model of Solara Active Pharma Sciences.
Key Ownership Highlights
The promoter group holds a significant portion of Solara's shares, with Devicam Capital LLP being the largest holder.
- FIIs and Mutual Funds are key institutional investors.
- Non-institutional investors hold a substantial share.
- The rights issue in 2024 impacted the capital structure.
- Understanding the ownership structure is vital for assessing the company.
Solara Active Pharma Sciences PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Solara Active Pharma Sciences’s Board?
The Board of Directors of Solara Active Pharma Sciences, as of June 2025, includes a blend of executive, non-executive, and independent directors. Key members include Sandeep Rao (Managing Director & CEO), Mohan Muthunarayanan (Executive Director & COO), and Arun Kumar (Founder & Non-Executive Director). The independent directors, such as Ramakrishnan R. (Chairman), Dr. Kausalya Santhanam, Rajendra Srivastava, and Rajiv Nabar, bring diverse expertise to the company's governance.
Kartheek Raju, a non-executive director, brings experience from investment and consulting, with a focus on Pharma, Power, and Commercial Real Estate sectors. Arun Kumar, the founder, provides entrepreneurial experience from establishing Strides Pharma Science Limited and co-founding SeQuent Scientific Limited. These individuals, along with other board members, guide the strategic direction of Solara Active Pharma Sciences, ensuring a balance of experience and independence.
| Director | Position | Details |
|---|---|---|
| Sandeep Rao | Managing Director & CEO | Appointed February 21, 2025, for three years. |
| Mohan Muthunarayanan | Executive Director & COO | Oversees operations. |
| Arun Kumar | Founder & Non-Executive Director | Brings entrepreneurial experience. |
| Ramakrishnan R. | Independent Director & Chairman | Ensures governance and oversight. |
Solara ownership structure shows that promoters held 37.94% of the shares as of March 2025. However, a significant portion, 34.64%, was pledged. Institutional investors, including FIIs with 14.63%, also play a crucial role. The presence of independent directors is intended to provide a balance and ensure good governance. Recent changes, such as Sandeep Rao's appointment as CEO in February 2025, and the appointment of Mr. Sarat Kumar as CFO, signal potential shifts in decision-making and strategic direction. For more insights, read about the Marketing Strategy of Solara Active Pharma Sciences.
Key Takeaways on Solara Ownership
The board includes a mix of executive, non-executive, and independent directors, ensuring diverse expertise and oversight.
- Promoters hold the largest share, but a significant portion is pledged.
- Institutional investors, particularly FIIs, have a notable stake.
- Recent leadership changes may influence strategic decisions.
- Independent directors are present to provide governance balance.
Solara Active Pharma Sciences Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Solara Active Pharma Sciences’s Ownership Landscape?
Over the past few years, Solara Active Pharma Sciences has seen significant shifts in its ownership structure. A key development is the planned demerger of its Contract Research and Manufacturing Services (CRAMS) and Polymers business. This strategic move, approved by the Board of Directors on January 24, 2025, aims to unlock value and streamline operations. As part of this, Synthix Global Pharma Solutions Limited, a wholly-owned subsidiary, was incorporated on April 29, 2025. Existing shareholders of Solara are expected to receive proportional shareholding in the new company upon demerger, indicating a potential redistribution of Solara ownership.
Another crucial event was the rights issue that closed on June 11, 2024, which raised ₹449.95 crore. This capital injection, along with debt reduction, has improved the company's financial risk profile. Furthermore, the company is making further calls on the partly paid-up shares, with the first call approved on March 26, 2025, with a record date of April 4, 2025. These actions influence the Solara shareholding and the overall ownership landscape.
| Ownership Category | March 2025 | Previous Quarter | Change |
|---|---|---|---|
| Promoters | 37.94% | 37.23% | Increased |
| Foreign Institutional Investors (FIIs) | 14.63% | 14.67% | Decreased |
| Mutual Funds | 1.28% | 1.28% | No Change |
In terms of ownership trends as of March 2025, promoters have slightly increased their holdings from 37.23% to 37.94%. However, a substantial portion of promoter shares, 34.64%, remains pledged. FIIs have shown a slight decrease in holdings, and mutual fund holdings have remained constant. These changes reflect the ongoing evolution of Solara ownership and the interests of various investors in the API manufacturer.
Demerger Plan
The demerger of CRAMS and Polymers business aims to unlock value and streamline operations. This strategic move is expected to create a new entity for these high-growth verticals.
Rights Issue
The rights issue, completed in June 2024, raised ₹449.95 crore, improving the company's financial position. This capital infusion is a key factor in Solara's financial strategy.
Ownership Changes
Promoters increased their holdings slightly, while FIIs showed a small decrease. Mutual fund holdings remained unchanged, reflecting investor sentiment.
Financial Performance
The company reported a net profit of ₹5.99 crore for the quarter ending March 2025, a significant turnaround. Despite a decline in net sales, operating profit margins improved.
Solara Active Pharma Sciences Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of Solara Active Pharma Sciences Company?
- What is Competitive Landscape of Solara Active Pharma Sciences Company?
- What is Growth Strategy and Future Prospects of Solara Active Pharma Sciences Company?
- How Does Solara Active Pharma Sciences Company Work?
- What is Sales and Marketing Strategy of Solara Active Pharma Sciences Company?
- What is Brief History of Solara Active Pharma Sciences Company?
- What is Customer Demographics and Target Market of Solara Active Pharma Sciences Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.